Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

ImmunityBio (IBRX) Non-Current Receivables: 2019-2025

Historic Non-Current Receivables for ImmunityBio (IBRX) over the last 5 years, with Sep 2025 value amounting to $7.3 million.

  • ImmunityBio's Non-Current Receivables rose 3.54% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 3.54%. This contributed to the annual value of $7.1 million for FY2024, which is 3.33% up from last year.
  • Latest data reveals that ImmunityBio reported Non-Current Receivables of $7.3 million as of Q3 2025, which was up 0.87% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Non-Current Receivables registered a high of $7.3 million during Q3 2025, and its lowest value of $6.2 million during Q1 2021.
  • Over the past 3 years, ImmunityBio's median Non-Current Receivables value was $7.0 million (recorded in 2024), while the average stood at $7.0 million.
  • Data for ImmunityBio's Non-Current Receivables shows a peak YoY increased of 4.42% (in 2021) over the last 5 years.
  • Over the past 5 years, ImmunityBio's Non-Current Receivables (Quarterly) stood at $6.4 million in 2021, then rose by 3.58% to $6.6 million in 2022, then rose by 4.09% to $6.9 million in 2023, then increased by 3.33% to $7.1 million in 2024, then climbed by 3.54% to $7.3 million in 2025.
  • Its Non-Current Receivables stands at $7.3 million for Q3 2025, versus $7.3 million for Q2 2025 and $7.2 million for Q1 2025.